Author: Willem van Lawick

Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Dr. Robert Soiffer and Mr. Berndt Modig to be appointed as new members of the Supervisory Board. (more…)

– Significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group
– Zero patients developed grade III-IV acute Graft-versus-Host-Disease upon infusion of ATIR101™
– Initiation of a randomised Phase III trial in the second half of 2016
– Management will host a webcast to discuss the data today at 18.00 CET

Amsterdam, The Netherlands, April 4, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today presents positive results on the primary endpoint of its single dose Phase II trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ at the 42nd Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
The data presented in session O042 by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and the principal investigator for the trial, confirms that ATIR101™ can be safely infused, does not cause grade III-IV Graft-versus-Host-Disease (GVHD) and shows a significant reduction in Transplant Related Mortality (TRM) and a significant improvement in Overall Survival (OS) in comparison to a historical control group of patients undergoing a T-cell depleted haploidentical donor transplantation only. (more…)

~ Additional ATIR101TM data also selected for three poster presentations at EBMT ~

Amsterdam, The Netherlands, March 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that key data from the Company’s ongoing single-dose Phase II clinical trial (NCT01794299/EudraCT 2012-004461- 41) with its lead product ATIR101TM has been selected for an oral presentation to discuss the top-line data at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on April 3-6, 2016 in Valencia, Spain. Three abstracts on additional ATIR101TM data and the ATIR101TM development program have also been accepted for poster presentations at EBMT.
The oral presentation entitled ‘Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALL’ will be delivered in Room B6 on Monday April 4, 2016 at 16:05 CET by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and principal investigator for the study. (more…)

~ LLS will fund the Phase II development via an equity investment in Kiadis Pharma ~

Amsterdam, The Netherlands, February 1, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) under which LLS will fund the Phase II development of Kiadis Pharma’s lead product, ATIR101™, through an equity investment of approximately $1 million. (more…)

Funding will enable new intranasal vaccine SynGEM® to be tested in phase I and IIa human clinical trials

Groningen, the Netherlands, January 20, 2016 –Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today announced that it has secured a €3.7 million (£2.77 million) translational fund award from the Wellcome Trust to progress its proprietary intranasal Respiratory Syncytial Virus (RSV) vaccine, SynGEM®, into phase I and IIa human clinical trials. The trials will be led by world-leading expert in RSV and member of Mucosis’s Scientific Advisory Board, Professor Peter Openshaw FRCP FMedSci and Dr. Christopher Chiu of the National Heart & Lung Institute, Imperial College London. (more…)